Oxurion NV
XBRU:OXUR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/GP
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Enterprise Value to Gross Profit (EV/GP) ratio compares a company`s total enterprise value to its gross profit. It shows how much investors are paying for each dollar of the company`s gross profit, including both equity and debt.
Valuation Scenarios
If EV/GP returns to its 5-Year Average (14 438.4), the stock would be worth €-2.14 (56 462% downside from current price).
| Scenario | EV/GP Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -25.6 | €0 |
0%
|
| 5-Year Average | 14 438.4 | €-2.14 |
-56 462%
|
| Industry Average | 2.5 | €-0 |
-110%
|
| Country Average | 4.7 | €-0 |
-118%
|
Forward EV/GP
Today’s price vs future gross profit
Peer Comparison
| Market Cap | EV/GP | P/E | ||||
|---|---|---|---|---|---|---|
| BE |
|
Oxurion NV
XBRU:OXUR
|
337k EUR | -25.6 | 0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 0 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 9.6 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
177.8B USD | 7.2 | 23 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 7.5 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 769.8 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 9.6 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 4.2 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 11.9 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 26 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 6.4 | 29.5 |
Market Distribution
| Min | 0.3 |
| 30th Percentile | 2.7 |
| Median | 4.7 |
| 70th Percentile | 9.5 |
| Max | 602.7 |
Other Multiples
Oxurion NV
Glance View
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases. The company is headquartered in Heverlee, Vlaams-Brabant and currently employs 42 full-time employees. The company went IPO on 2006-07-07. Its lead product, JETREA (ocriplasmin), has been approved by the United States Food and Drug Administration for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. Oxurion partners with Alcon (Novartis) for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns, which was launched in the United Kingdom and Germany. In addition, it also explores anti-PIGF (Placental Growth Factor), also referred to as TB-403, for the treatment of ophthalmic and oncology indications. The firm is active domestically, as well as operates through offices located in the United States and Ireland.
